Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Aggreko loses power on UBS downgrade

Mon, 11th Apr 2016 09:12

(ShareCast News) - Temporary power provider Aggreko was under the cosh after UBS downgraded the stock to 'sell' from 'neutral' and slashed the price target to 800p from 1,050p."Weak markets have undoubtedly been a headwind for Aggreko for the past 3 years, but we now believe that Aggreko's problems are structural too," the bank said.As the power rental market has matured, Aggreko's competitive advantage has been eroded, UBS said.As a result, it expects pricing to come under increasing pressure, eating through cost savings and further compressing return on invested capital."A new product line is likely necessary to reinvent Aggreko, but we wouldn't expect to see a material benefit until 2020+m," it said, adding that it expects to see continued earnings risk and for the valuation to remain constrained.UBS said Aggreko urgently needs to launch a new product before it can hope to rebuild a unique competitive advantage and hit targets for return on capital employed.At 0920 BST, Aggreko shares were down 3.2% to 1,010p.

Related Shares

More News
9 Dec 2022 10:27

Aggreko to buy Crestchic in £122m deal

(Sharecast News) - Temporary power supplier Aggreko said on Friday that it has agreed to buy specialist equipment provider Crestchic in a £122m d...

6 Aug 2021 18:20

IN BRIEF: Edinburgh court sanctions Albion's takeover of Aggreko

IN BRIEF: Edinburgh court sanctions Albion's takeover of Aggreko

2 Aug 2021 10:07

Albion puts in place financing for GBP2.32 billion Aggreko acquisition

Albion puts in place financing for GBP2.32 billion Aggreko acquisition

8 Jul 2021 21:32

IN BRIEF: Aggreko takeover clears antitrust and regulatory hurdle

IN BRIEF: Aggreko takeover clears antitrust and regulatory hurdle

26 May 2021 11:15

TOP NEWS: Carlyle offers GBP958 million for asthma drug maker Vectura

TOP NEWS: Carlyle offers GBP958 million for asthma drug maker Vectura

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.